Asunra is a brand name for Deferasirox, available at 400 mg in dispersible tablet form. Alternative brands that contain Deferasirox are shown below, cheapest first, to help compare prices. Price on record: Tk 187.00 per unit. A pack price of Tk 5610.00 (3 x 10) is also listed. The listed drug class is Antidote preparations. Asunra is produced by Novartis (Bangladesh) Ltd. The indications section of the listing begins: “Deferasirox is indicated for the treatment of chronic iron overload due to blood transfusions in adult and paediatric patients (aged 2 years and over)”. Use this information only as a reference: a medicine should be taken as advised by a doctor, and a pharmacist can answer questions about dose and brand substitution.
There are 2 brands of Deferasirox listed in Bangladesh. 1 of them has a lower unit price than Asunra. The lowest listed price is Asunra 100 mg Dispersible Tablet at ৳ 50.00 per unit.
Deferasirox is indicated for the treatment of chronic iron overload due to blood transfusions in adult and paediatric patients (aged 2 years and over).
Pharmacology
Deferasirox is an orally active chelator that is selective for iron (as Fe3+ ). It is a tridentate ligand that binds iron with high affinity in a 2:1 ratio. Although deferasirox has very low affinity for zinc and copper there are variable decreases in the serum concentration of these trace metals after the administration of deferasirox. The clinical significance of these decreases is uncertain.
Dosage & Administration
2 years children & Adult Dose:
Chronic Iron overload: Initially, 20 mg/kg daily. Adjust dosage every 3-6 months as needed based on trends in serum ferritin concentrations (monitor monthly). Adjust dosage in increments of 5 or 10 mg/kg daily (up to maximum dosage of 30 mg/kg daily) according to the patient’s clinical response and therapeutic goals. Consider temporarily interrupting therapy if serum ferritin concentrations are consistently <500 mcg/L.
Interaction
May chelate Al when used with Al-containing antacids. Decreased exposure with colestyramine and potent inducers of UGT enzymes (e.g. carbamazepine, rifampicin, phenytoin). May increase serum concentration of CYP1A2 (e.g. duloxetine, theophylline) and CYP2C8 (e.g. repaglinide, paclitaxel) substrates, and decrease serum concentrations of CYP3A4 substrates (e.g. ciclosporin, hormonal contraceptives, simvastatin).
Contraindications
Creatinine clearance <40 mL/min or serum creatinine >2 times the age-appropriate upper limit of normal. High risk myelodysplastic syndrome (MDS) patients and patients with other hematological and non-hematological malignancies who are not expected to benefit from chelation therapy due to the rapid progression of their disease. Hypersensitivity to the active substance or to any of the excipients.
Pregnancy: No clinical data on exposed pregnancies are available for deferasirox. Studies in animals have shown some reproductive toxicity at maternally toxic doses. The potential risk for humans is unknown. As a precaution, it is recommended that Deferasirox not be used during pregnancy unless clearly necessary.
Breast-feeding: In animal studies, Deferasirox was found to be rapidly and extensively secreted into maternal milk. No effect on the offspring was noted. It is not known if Deferasirox is secreted into human milk. Breast-feeding while taking Deferasirox is not recommended.
Precautions & Warnings
Moderate hepatic impairment. Children. Pregnancy and lactation.
Overdose Effects
Single doses up to 40 mg/kg in normal subjects have been well tolerated. Acute signs of overdose may include nausea, vomiting, headache, and diarrhea. Overdose may be treated by induction of emesis or by gastric lavage, and by symptomatic treatment.
Storage Conditions
Store at 25° C. Protect from moisture.
Alternative brands of Deferasirox
Other brands with the same generic name, cheapest first.